PharmTech Drug Digest 11.20
News|Articles|September 30, 2016

Tapemark Showcases Transdermal, Oral Thin Film, and Topical Drug-Delivery Systems at CPhI

Tapemark, a full-service CDMO specializing in transdermal, oral thin film, and topical drug-delivery technologies, is exhibiting at CPhI.

Tapemark, a full-service CDMO specializing in transdermal, oral thin film, and topical drug-delivery technologies, is exhibiting at CPhI. Whether it’s launching a new product, or looking for new delivery forms to extend the reach of existing ones, pharmaceutical companies have the option of partnering with CDMOs to turn their vision into reality. With so many steps-from formulation through commercialization-and stringent regulatory requirements along the way, it can be confusing to know which CDMO can truly meet their specific needs.

Visitors can find out more about Tapemark’s offerings at Stand 3G47 such as:

  • Transdermal-Tapemark specializes in both passive and active transdermal technologies, including the IontoPatch product line based on iontophoresis technology. Transdermal patches provide accurate, steady, and controlled dosages, avoid first-pass metabolism, and improve patient safety, convenience, and compliance.

  • Oral-thin film-SoluStrip is a soluble oral and oral transmucosal (buccal, sublingual) thin film. Oral transmucosal thin film drug delivery avoids first-pass metabolism, gastrointestinal side effects, and can provide rapid onset of action.

  • Topical drug delivery-The Snapplicator and Snap! Drug-delivery systems provide a safe, easy, and quick one-handed way to apply an accurate dosage of creams, gels, pastes, and lotions.

Source: Tapemark, Stand 3G47


Related to this article

white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.